A Pilot Study of Microbiome in Patients With Autism Spectrum Disorder and Their Unaffected Siblings

Completed

• Conditions: Autism Spectrum Disorder
• Interventions: Other: Psychiatric diagnosis; Other: ASD diagnosis

• Registration Number: NCT05038748
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

The primary aims are to identify important gut microbiota signatures for youth with ASD, to identify dysbiosis features for different levels of ASD features and clinical courses, to search the possibility to intervene the disease course if we can tease out the dysbiosis responsible for the flare-up and improvement of the symptoms of the disease. The secondary aims are to identify the clinical and neuropsychological measures that are associated with direct and indirect regulation or interactions from gut-brain axis signaling, and based our preliminary results on reducing the measures for future large-scale microbiome study in ASD.

Detailed Description

Background: Despite increased public awareness of autism spectrum d isorder (ASD) and extensive research on this neurodevelopmental disorder in the past decades, the underlying mechanisms of ASD remain unclear, and ASD is still recognized as having the highest disease and care burden among child psychiatric disorders regarding its long-term impairment across the lifespan. Hence, identifying the biomarkers for early detection and effective biological treatments for ASD is among the most challenging tasks all over the world. The concerns about physical comorbidities such as immune dysregulation, allergy, and gastrointestinal issues, etc. emerged in the recent decade. Hence, the new perspective of searching for the underlying mechanism for ASD also targets the associations between microbiota and ASD. However, despite many microbiome studies in ASD, they provided limited knowledge about the specific link that particular imbalance gut bacteria could affect the behavioral deficits in ASD because lack of consideration of the clinical and genetic heterogeneity of ASD. With only a few studies examining the well-defined ASD-related impairments, the GI system dysfunction, and the microbiomes, the associations among ASD-related symptoms, GI symptoms, and microbiota remain indistinct. Therefore, the investigators propose this pilot study to fill the gap between the potential role of microbiome as a biomarker for ASD to facilitate developing the treatment for ASD.

Method and material: The case-sibling control study design will be used to investigate microbiome in 60 probands with ASD, aged 7-25 yrs old, and 30 unaffected siblings either from the PI Gau's ASD cohort or the Department of Psychiatry, National Taiwan University Hospital. The parents of all the subjects will receive the Autism Diagnostic Interview-Revised (ADI-R) interviews and report on the questionnaires regarding autistic symptoms, emotional/behavioral problems, social functions, G-I symptoms, and life quality. The ASD and sibling subjects will receive the Autism Diagnostic Observation Scale and neuropsychological tasks. The experiment of microbiome will be conducted by the core lab of microbiome (co-PI Ni) at the college of medicine, National Taiwan University. The data analyses will combine microbiomics and the extensive behaviors/cognitive function variables to establish an objective potential pipeline.

Anticipated outcome: With the accomplishment of this project, the investigators will establish the comprehensive yet fewer bios for the ASD risk bio-factors in Asia, and provide the potential clinical interview and assessments related to GI symptoms regulated by microbiota. The potential biomarkers may be further used to developing the treatment for ASD.

Significance: Several features of this project constitute its significance: a wealth of measures of ASD phenotypes (valid phenotype), ASD as a catastrophic disease (importance), the first ASD study with unaffected sibling design for microbiomics studies in ASD (originality), and new approaches and technologies (novelty) for searching microbiomics in ASD.

Study Timeline

• Study Start: 2019-01-01
• Primary Completion: 2020-12-31
• Study Completion: 2020-12-31
• Status Verified: 2021-01
• Study First Submitted: 2021-09-01
• Study First Submitted QC: 2021-09-01
• Last Update Submitted: 2021-09-08
• Study First Posted: 2021-09-09
• Last Update Posted: 2021-09-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• a clinical diagnosis of ASD defined by the DSM-IV confirmed by ADI-R or ADOS and also clinical reappraisal based on the newly release DSM-5 criteria for ASD
• ages range from 7 to 25 at the time now
• at least one biological parent
• parents that are both Han Chinese in Taiwan

Read More

Exclusion Criteria

• intellectual disability
• epilepsy
• ADHD
• autoimmune diseases

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Sibling group	Psychiatric diagnosis	30 unaffected siblings of ASD youths
ASD group	Psychiatric diagnosis	80 youths with the clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
ASD group	ASD diagnosis	80 youths with the clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
TD group	Psychiatric diagnosis	40 healthy typical developing(TD) control from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007

Primary Outcome Measures

Name	Time	Method
Autism Diagnostic Interview-Revised (ADI-R)	1 hour	Including reciprocal social interaction, communication, and repetitive behaviors and stereotyped patterns, for children with a mental age from about 18 months into adulthood. The coding of some items is converted to numeric scores "0" if no evidence of abnormality exists, "1" if some evidence of abnormality exists, and "2" if evidence of marked abnormality. Higher scores mean more severe clinical deficits.
Autism Diagnostic Observation Scale (ADOS)	1 hour	Including communication, social interaction, creativity, stereotyped behaviors and restricted interests. The coding of some items is converted to numeric scores "0" if no evidence of abnormality exists, "1" if some evidence of abnormality exists, and "2" if evidence of marked abnormality. Higher scores mean more severe clinical deficits.

Trial Locations

Locations (1)

National Taiwan Univeristy Hospital; 🇨🇳 Taipei, Taiwan